Over the last ten years, there have been significant advancements in the field of cancer biology. These include major breakthroughs in genomics technology, which have allowed scientists to obtain DNA sequences of thousands of tumours. Additionally, researchers have been able to analyse the gene expression profiles of tumours at the individual cell level. Furthermore, the functional properties of genes have been studied through comprehensive CRISPR screens of the entire genome, leading to the ident. Regrettably, many therapeutic targets arising from these advancements have been classified as "undruggable" based on traditional criteria ( ). These targets often include extensive protein-protein interaction surfaces that do not have readily identifiable pockets for binding ligands. However, the drug discovery community has shown a growing commitment to the challenge of developing drugs for targets that were previously considered impossible to drug. As a result, researchers have focused on developing new methods to target previously considered "undruggable" targets, such as KRAS ( ). The targeting of KRAS with drugs aims to analyse the variables that led to the development of innovative approaches to address this challenging and difficult-to-drug target ( ). Another successful example of targeting "undruggable" targets is PROTAC ( ). PROTAC can degrade the protein of interest using the ubiquitin mechanism in the cell ( ). The last successful example is that Prodrugs have been used in the targeting of "undruggable" targets ).